Loxo Oncology, Inc. (NASDAQ:LOXO) is set to post its quarterly earnings results before the market opens on Monday, October 30th. Analysts expect Loxo Oncology to post earnings of ($1.26) per share for the quarter.

Loxo Oncology (NASDAQ:LOXO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.99) by ($0.15). During the same period last year, the business posted ($0.77) earnings per share. On average, analysts expect Loxo Oncology to post $-4.49 EPS for the current fiscal year and $-4.52 EPS for the next fiscal year.

Shares of Loxo Oncology, Inc. (NASDAQ:LOXO) traded down 1.06% during trading on Monday, hitting $85.70. The company had a trading volume of 162,022 shares. Loxo Oncology, Inc. has a 12-month low of $17.14 and a 12-month high of $95.92. The stock’s market cap is $2.56 billion. The firm has a 50 day moving average of $86.48 and a 200 day moving average of $69.16.

A number of research firms recently commented on LOXO. BidaskClub upgraded shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Zacks Investment Research upgraded shares of Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 price objective for the company in a research report on Wednesday, August 9th. Stifel Nicolaus restated a “buy” rating and issued a $94.00 price objective (up previously from $71.00) on shares of Loxo Oncology in a research report on Thursday, August 10th. BTIG Research restated a “buy” rating and issued a $75.00 price objective on shares of Loxo Oncology in a research report on Thursday, August 3rd. Finally, Ifs Securities restated an “outperform” rating on shares of Loxo Oncology in a research report on Tuesday, August 8th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Loxo Oncology presently has an average rating of “Buy” and an average target price of $80.02.

ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/10/23/loxo-oncology-inc-loxo-set-to-announce-earnings-on-monday.html.

In related news, VP Jennifer Burstein sold 1,700 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $73.73, for a total value of $125,341.00. Following the completion of the sale, the vice president now directly owns 1,700 shares in the company, valued at approximately $125,341. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joshua H. Bilenker sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $73.56, for a total transaction of $1,103,400.00. Following the completion of the sale, the chief executive officer now owns 196,207 shares of the company’s stock, valued at $14,432,986.92. The disclosure for this sale can be found here. Insiders sold a total of 89,896 shares of company stock valued at $7,315,562 over the last quarter. 44.40% of the stock is currently owned by company insiders.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Earnings History for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.